According to Sinopharm Hyundai's announcement, the company has received the “Drug Registration Certificate” for tacrolimus ointment approved and issued by the State Drug Administration, covering both 0.03% and 0.1% specifications. The registration classification is classified as a chemical class 4, which is considered to have passed the consistency evaluation. This drug is a non-hormonal immunomodulatory drug and is suitable for patients with moderate to severe atopic dermatitis. Up to now, the company has invested about 15.2541 million yuan in R&D for this project. This certification has enriched the company's dermatological drug product range and will not have a significant impact on current business performance.

According to Sinopharm Hyundai's announcement, the company has received the “Drug Registration Certificate” for tacrolimus ointment approved and issued by the State Drug Administration, covering both 0.03% and 0.1% specifications. The registration classification is classified as a chemical class 4, which is considered to have passed the consistency evaluation. This drug is a non-hormonal immunomodulatory drug and is suitable for patients with moderate to severe atopic dermatitis. Up to now, the company has invested about 15.2541 million yuan in R&D for this project. This certification has enriched the company's dermatological drug product range and will not have a significant impact on current business performance.